Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23837412 | 0.91 | CYP1A2 (0.30) | — | |
| SCHEMBL19228055 | 0.88 | — | — | |
| SCHEMBL18797988 | 0.88 | — | — | |
| SCHEMBL18797983 | 0.87 | — | — | |
| SCHEMBL23129662 | 0.84 | KMT2A (0.32) | USP2HTTKMT2ARAB9A | |
| SCHEMBL17347818 | 0.84 | KMT2A (0.32) | USP2HTTKMT2ARAB9A | |
| SCHEMBL18797990 | 0.83 | MTNR1A (0.32) | — | |
| SCHEMBL17337133 | 0.82 | RAB9A (0.35) | HTTKMT2ARAB9A | |
| SCHEMBL17337541 | 0.82 | RAB9A (0.35) | HTTKMT2ARAB9A | |
| SCHEMBL17337334 | 0.80 | TSHR (0.37) | USP2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926336-B2 | Beta-lactamase inhibitors | VENATORX PHARMACEUTICALS (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342092-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | USP2 869/4885HTT 4789/4885KMT2A 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.